Pure People

Pure is set apart by its exceptional personnel. The company was founded by Chief Scientist Dr. William Hildebrand, who has been awarded over $40 million in grants, authored over 120 publications, and holds 77 patents in fields related to the discovery and use of the HLA protein technology he has developed.

Chief Scientist

achievements and background

Dr. William Hildebrand received his PhD from. Southern Illinois University and conducted post-doctoral research at Stanford University under Dr. Peter Parham. Dr. Hildebrand is the Presbyterian Health Foundation Endowed Professor and the Robert Glenn Rapp Foundation Presidential Professor in the Department of Microbiology and Immunology at The University of Oklahoma Health Sciences Center.

He has been a CLIA Accredited Clinical HLA Laboratory Director and an American Board for Histocompatibility and Immunogenetics Diplomate since 1998. Dr. Hildebrand has been awarded over $40M in grants from Oklahoma State and Federal government agencies as well as private corporations. He has authored over 120 publications, reviews, ad book chapters in peer-reviewed industry works and popular science journals. He was Associate Editor of the Journal of Immunology from 2006-2010. He has served on editorial, advisory, and national review panel boards for the NIH, Center for HIV/AIDS Vaccine Immunology (CHAVI), American Society for Hematology , NIAID and the National Marrow Donor Program. He holds 77 patents in fields related to the discovery and use of the HLA protein technology he has developed. He has appeared on numerous radio and television news programs and in public service announcements highlighting his research. Dr. Hildebrand is a frequent invited keynote speaker and advisor to international conferences and private industry companies.

Dr. Hildebrand founded Pure Protein LLC in 1999 and still serves as its Chief Scientist. He founded two additional subsidiary companies, Pure Transplant and Pure Vaccine Solutions in 2003. These companies were founded on the principle that a ready source of native HLA proteins would contribute to modulating and understanding autoimmune, transplant, pathogen, and vaccine derived immune responses.